SCHEMBL2228293

SCHEMBL2228293

Cc1c2c(nc3cc(C(=O)O)ccc13)CCCC2

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.52
MAPT P10636 7/20 0.52
KMT2A Q03164 3/20 0.52
HTT P42858 2/20 0.52
POLB P06746 3/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
KDM4E B2RXH2 3/20 0.50
HPGD P15428 2/20 0.50
NPC1 O15118 3/20 0.49
RAB9A P51151 3/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
MAPK1 P28482 3/20 0.49
NPSR1 Q6W5P4 1/20 0.49
RXFP1 Q9HBX9 1/20 0.49
BLM P54132 1/20 0.49
SMYD3 Q9H7B4 2/20 0.48
TSHR P16473 1/20 0.48
ACHE P22303 1/20 0.48
TP53 P04637 1/20 0.47
MEN1 O00255 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2227205 0.85 NPC1 (0.51) ALDH1A1MAPTKMT2AHTTPOLB
SCHEMBL2225232 0.84 MAPT (0.56) ALDH1A1MAPTKMT2AHTTPOLB
SCHEMBL30411706 0.83 ACHE (0.63) ALDH1A1KMT2AKDM4EMAPK1TSHR
SCHEMBL2218702 0.83 MAPT (0.72) ALDH1A1MAPTKMT2AHTTPOLB
SCHEMBL2228808 0.83 TP53 (0.59) ALDH1A1MAPTKMT2APOLBNPC1
SCHEMBL2228741 0.82 MAPT (0.70) ALDH1A1MAPTKMT2AHTTPOLB
SCHEMBL22703723 0.77 POLB (0.53) ALDH1A1MAPTKMT2APOLBL3MBTL1
SCHEMBL2229105 0.76 MAPT (0.63) ALDH1A1MAPTKMT2AHTTPOLB
SCHEMBL11833191 0.76 POLB (0.45) ALDH1A1MAPTKMT2AHTTPOLB
SCHEMBL527199 0.76 ACHE (0.65) ALDH1A1MAPTKMT2AKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9328093-B2 Selective inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications HYBRIGENICS SA (FR) 2016-05-03 US disclosed
CN-102781919-B As the amido acridine derivatives of the selective depressant of ubiquitin-specific protease 7 HYBRIGENICS S.A. (FR) 2016-01-20 CN disclosed
US-20150072973-A1 NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2015-03-12 US disclosed
EP-2523938-B1 Amidoacridine derivatives useful as selective inhibitors of ubiquitin specific protease 7 HYBRIGENICS SA (FR) 2014-09-03 EP disclosed
US-20130023521-A1 NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2013-01-24 US disclosed
EP-2523938-A1 AMIDOACRIDINE DERIVATIVES USEFUL AS SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 Hybrigenics S.A. (FR) 2012-11-21 EP disclosed
CN-102781919-A Amidoacridine derivatives useful as selective inhibitors of ubiquitin specific protease 7 HYBRIGENICS SA 2012-11-14 CN disclosed
WO-2011086178-A1 AMIDOACRIDINE DERIVATIVES USEFUL AS SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 HYBRIGENICS SA (FR) 2011-07-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130023521-A1 NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS USP7, SENP7, PSMA7 ALDH1A1 3216/4885MAPT 704/4885KMT2A 2349/4885
US-20150072973-A1 NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS USP7, SENP7, PSMA7 ALDH1A1 3216/4885MAPT 704/4885KMT2A 2349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.